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Background: Vascular endothelial growth factor (VEGF) is a key regulator of physiologic and pathogenic
angiogenesis in diseases such as cancer and diabetic retinopathy. It is known that cysteine proteases from plants,
like bromelain and papain are capable to suppress inflammatory activation. Recent studies have demonstrated that
they may interfere with angiogenesis related pathways as well. The aim of this study was to investigate the anti-
angiogenic effects of papain on human umbilical vein endothelial cells (HUVEC) in vitro.
Methods: Cell viability after prolonged treatment with papain was investigated by life cell staining and lactate
dehydrogenase release assay. Angiogenic activation was assessed by ELISA against phosphorylated proteins AKT,
MEK1/2, ERK1/2, SAPK/JNK and p38-MAPK. Growth inhibition was determined by means of an MTT-assay and cell
migration by means of a scratch assay. Capability to form a capillary network was investigated using a tube
formation assay.
Results: Papain did not induce proteolysis or cell detachment of HUVEC in a concentration range between 0 and
25 μg/mL. Four hours treatment with 10 μg/mL papain resulted in a reduced susceptibility of endothelial cells to
activation by VEGF as determined by phosphorylation levels of Akt, MEK1/2, SAPK/JNK. Papain exerted a distinct
inhibitory effect on cell growth, cell migration and tube formation with inhibition of tube formation detectable at
concentrations as low as 1 μg/mL. Bromelain and ficin displayed similar effects with regard to cell growth and tube
formation.
Conclusion: Papain showed a strong anti-angiogenic effect in VEGF activated HUVEC. This effect may be due to
interference with AKT, MEK1/2 and SAPK/JNK phosphorylation. Two other plant derived cysteine proteases
displayed similar inhibition of HUVEC cell growth and tube formation. These findings indicate that plant proteolytic
enzymes may have potential as preventive and therapeutic agents against angiogenesis related human diseases.
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Angiogenesis is the formation of new capillary blood
vessels by a process of sprouting from pre-existing ves-
sels and occurs during development as well as in a num-
ber of physiological and pathological settings. It plays a
key role in chronic human diseases such as ocular dis-
orders, rheumatoid arthritis and cancer [1]. In solid
tumors, induction of angiogenesis is a necessary pre-
condition for tumor growth beyond the size of a* Correspondence: thomas.mohr@mohrkeg.co.at
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distribution, and reproduction in any mediumpinhead [2]. Mounting evidence suggests an important
role for angiogenesis in hematologic malignancies as
well [3]. In cardiovascular disease, the role of angiogen-
esis is much less clear. Angiogenic therapy is considered
to be a promising approach to treat cardiovascular dis-
ease [4]. On the other hand, angiogenesis within the
vessel wall is positively correlated with the development
of atherosclerosis, because microvessels are abundant in
atherosclerotic lesions and contribute significantly to
disease progression and plaque instability [5,6].
Angiogenesis is mediated via a number of different
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extracellular domain of their receptors, dimerization
and autophosphorylation of the intracellular receptor
tyrosine kinases occur, resulting in the activation of a
cascade of downstream pathways including the PI3K
pathway (cell survival), Src (vascular permeability),
FAK, p38-MAPK and Smad 2/3 (cell migration) and
PLCγ pathways (proliferation) [8].
Cysteine proteases from plants, namely pineapple, figs
and papaya have been used in complementary medicine for
decades and are currently under investigation in connection
with diseases involving inflammation. The level of proof,
method of enzyme administration and dose and quality of
the studies vary, but beneficial effects were observed in a
number of different models, including experimental allergic
encephalomyelitis (EAE) model of the human autoimmune
disease multiple sclerosis, carrageenan-induced pleurisy
in the rat, immunologically mediated arteriosclerosis in
rat aortic allografts, rheumatologic diseases in mice and
humans, and allergic asthma (reviewed in [9] and [10]).
Some studies demonstrated that bromelain had an efficacy
similar to standard anti-inflammatory drugs such as de-
xamethasone [11,12] or non-steroidal anti-inflammatory
agents (NSAIDs) [13-16]. However, the exact mode of ac-
tion is unclear. Early studies suggested a modulation of the
expression of surface molecules, particularly on immuno-
competent cells [17] which likely interferes with cell-cell
communication [18-20]. More recent studies found that
cysteine proteases from plants prevent activation of inflam-
matory pathways such as the NF-κB, likely because of inter-
ference with the phosphorylation of IκBα [21-23]. Recently
it has been demonstrated that Bromelain does not only in-
hibit NF-κB activation, but phosphorylation of AKT, ERK1/
2, and p38-MAPK as well [21,22,24]. AKT, ERK1/2 and
p-38 MAPK constitute important regulatory proteins in
angiogenesis, regulating growth, migration and survival of
endothelial cells [8]. These data suggest that plant derived
cysteine proteases might not only display anti-inflammatory
but an anti-angiogenic properties as well. We have there-
fore decided to investigate the effect of papain on angio-
genic activation of HUVEC by VEGF. In this study we
present to our knowledge for the first time data on the
phosphorylation state of AKT, MEK1/2, ERK1/2, STAT3,
SAPK/JNK and on key endothelial functions such as cell
growth, migration and the capability to form tubes after
treatment with papain. To put these data into a more gen-
eral context, we tested whether other plant derived cysteine




Endothelial Basal Medium-2(MV) (Lonza, Verviers,
Belgium) was supplemented with 10% FCS (Fetal calfserum, PAA, Pasching, Austria), hydrocortisone, ascorbic
acid, gentamycin/amphotericin and growth factors bFGF,
EGF, IGF, VEGF, according to the instructions of the manu-
facturer (EGM). EGM without growth factors and 2.5%
serum supplement served as endothelial basal medium
(EBM). Papain from papaya latex (lyophilized powder,
chromatographically purified, cell culture grade, activity
10 U/mg protein) was purchased from Sigma-Aldrich,
Vienna. Bromelain (lyophilized powder,chromatographi-
cally purified, activity 10 U/mg,) and ficin (lyophilized pow-
der, chromatographically purified, activity 2 U/mg) were
purchased from Sigma Aldrich, Vienna.
Cell culture
HUVEC were purchased from Lonza (Verviers, Belgium)
and cultured on tissue culture flasks coated with human
fibronectin (Millipore, Vienna, Austria) in EGM con-
taining 10% FCS. Upon reaching 80% confluence, cells
were routinely passaged at a ratio of 1:2.
Cell viability
Cells were harvested by trypsin detachment, seeded into
fibronectin coated 12 well plates at a density of 120.000
cells per well and incubated with EGM to allow for the
formation of monolayers. After 24 hours, EGM was re-
placed with EBM containing 2.5% FCS, 10 ng/mL VEGF
(R&D Systems, Minneapolis, MN, USA), and 10 μg/mL
papain (Sigma-Aldrich, Vienna, Austria). After a further
10 hours incubation period, cells were stained with
2 μM Calcein (Sigma-Aldrich, Vienna, Austria) and pic-
tures were taken at 4 fold magnification using a Nikon
Eclipse Ti, the FITC filter set of the instrument and a
Nikon Digital Sight DS-Fi1C camera. Integrity of the
monolayer and viability of cells was assessed visually.
Lactate dehydrogenase (LDH) assays
Cells were seeded into 96-well microtiterplates at a density
of 5000 cells per well and incubated over night under
standard cell culture conditions in order to allow adher-
ence of the cells and formation of monolayers. The next
day medium was changed to EBM containing 2.5% FCS,
10 ng/mL VEGF and 10 respectively 25 μg/mL enzymes.
Cells were incubated for another 24 hrs and released lac-
tate dehydrogenase was determined using an 96-CytoTox
Assay Kit (Promega, Heidelberg, Germany) according to
the instructions of the manufacturer, including lysis of
total cells to determine maximal LDH release.
Cell lysis was calculated according to
%Lysis ¼ ODSample−ODuntreated
 
ODmax−ODuntreatedð Þ  100
with ODSample being the optical density of the sample,
Oduntreated being the optical density of the untreated
Mohr and Desser BMC Complementary and Alternative Medicine 2013, 13:231 Page 3 of 9
http://www.biomedcentral.com/1472-6882/13/231control and Odma the optical density of a cell lysate
obtained by treatement of cells with lysis buffer.
Immunofluorescence staining
Cells were seeded into HFN coated 8-well chamber
slides (Becton Dickinson, Franklin Lakes, NJ, USA), in-
cubated for 24 hours in EGM to allow initial attachment
and stimulated with 10 ng/mL LPS. Following treatment
with 10 μg/mL papain, cells were fixed with 2% parafor-
maldehyde for 15' at RT and permeabilized with 0.1%
Triton X-100 for 5' at RT. Cells were washed thrice with
300 μL PBS containing 1% FCS and incubated with pri-
mary antibody against VEGFR2 (mouse anti VEGFR2,
Abcam, Cambridge, UK, dilution 1:200). After three fur-
ther washes, cells were incubated with FITC labeled
anti-mouse antibody (Sigma-Aldrich). Cells were washed
for a final three times, enclosed in Vectrashield Hard-Set
(Vector labs, Burlington, CA, USA) and scanned using a
Zeiss LTM700 confocal laser microscope.
Multitarget ELISA
Phosphorylated proteins were determined using multi-
target ELISA kits (cell signaling technology, Beverly,
MA, USA). Briefly, cells were seeded in HFN coated
25 cm2 tissue culture flasks and incubated in EGM.
After 24 hours, EGM was changed to EBM. After a 24
hours starving period, medium was changed to EBM
containing 10 μg/mL papain and cells were incubated
for 4 hours. Cells were washed twice with PBS to re-
move papain and stimulated for 15 minutes with EBM
containing 10 ng/mL VEGF. Protein isolation and deter-
mination was carried out according to the instructions
of the manufacturer. Expression values were normalized
to protein content of the sample and expressed as fold
unstimulated control.
MTT-assay
Cells were seeded into 96-well microtiterplates at a
density of 2500 cells per well and incubated over night
under standard cell culture conditions in order to allow
adherence of the cells. The next day cells were treated
as indicated (10 ng/mL VEGF respectively 10 ng/mL
VEGF in combination with enzymes in EBM). Cells
were incubated for another 72 hrs. Cell growth was
determined using an EZ4U-assay (Biomedica, Vienna,
Austria) according to the instructions of the manufac-
turer. Cells incubated in EBM without growth factors
served as untreated control. Growth inhibition was cal-
culated as fold control.
Cell migration assay
Cells were detached by trypsin treatment and seeded
into fibronectin coated 12-well microtiter plates at dens-
ities of 120.000 cells/well. After 24 hours incubation inEGM, the monolayer was scratched using a 200 μL
pipette tip. Cells were stained with 1 μM calcein-AM
(Sigma-Aldrich, Vienna) and photographed using the
equipment as described above at 10 fold magnification.
Medium was changed to EBM with 10 ng/mL VEGF, or
10 ng/mL VEGF and papain as indicated and cells were
incubated for another 12 hrs. At the end of the incuba-
tion period, cells were again photographed as described
above. The Tscratch software [25] was used to quantify
the open area. Results were calculated as percent closure
after 14 hours with the area at start being set to 100%
and expressed as percent VEGF treated control.
Tube formation assay
Angiogenesis slides (Ibi, Martinsried, Germany) were
coated with 10 μL Matrigel per well (Growth Factor Re-
duced, Becton Dickinson) and incubated for 30 min at
37°C to allow for gelling. Endothelial cells were detached
by trypsin treatment and centrifugated for 5' at 300 g. The
pellet was washed once with PBS and adjusted to 100.000
cells per mL in EBM-2(MV) containing ascorbic acid and
hydrocortisone according to the instructions of the manu-
facturer and 10 ng/mL VEGF. Cell suspension (50 μL per
well) was seeded into each well. Cells were incubated to
allow initial cell attachment. After 4 hours, enzymes were
added as indicated and cells were further incubated. After
20 hours, cells were stained with 1 μM Calcein. Micro-
graphs of fluorescent cells were taken as described above.
Tube formation was quantified as described by Guidolin
et al. [26] using the Cell Profiler Software Package [27].
Briefly, images were converted into binary images by
thresholding as described by Otsu [28]. Areas with an ex-
tension of more than 125 μm in one direction were con-
sidered as tubes and selected for analysis, smaller areas
were discarded. A single pixel topological skeleton re-
presenting the tubular network was constructed and net-
work length was calculated by multiplying the pixel count
with a scaling factor representing microns per pixel. All
experiments were carried out in triplicates.
Statistical analysis
Data are presented as mean ± standard error of measure-
ment. Statistical analysis was carried out using GraphPad
Prism. Differences were assessed by one-way ANOVA
followed by Dunnett’s multiple comparison test.
Results
Cell viability
Proteases from various sources are routinely used in cell
culture to detach cells from surfaces of tissue culture
flasks. At higher concentrations and/or prolonged incu-
bation time proteases are capable of damaging cells. To
exclude this effects we first examined cell adhesion and
cell viability after prolonged exposure to papain (Figure 1).
AB
Figure 1 Effect of papain on cell viability (panel A) and lactate
dehydrogenase release (panel B). To test cell viability, HUVEC were
seeded into fibronectin coated microtiterplates and cultured in EGM.
After 24 hours medium was changed to EBM and cells were cultured for
10 hours in EBM containing 10 ng/mL VEGF or 10 ng/mL VEGF and 10
μg/mL papain. Cells were stained using life cell staining calcein-AM. Cells
were photographed at 4 fold magnification using a Nikon Eclipse Ti, the
FITC filter set of the instrument and a Nikon Digital Sight DS-Fi1C CCD
camera. Integrity of the monolayer and viability of cells was assessed
visually. To investigate lactate dehydrogenase release, HUVEC were
seeded into fibronectin coated 96-well microtiterplates and cultured in
EGM. After 24 hours medium was changed to EBM containing 10 ng/mL
VEGF or 10 ng/mL VEGF and papain at concentrations as indicated. After
48 hours, released lactate dehydrogenase was determined using a
96-Cytotoxassay kit. Data are shown as mean ± standard error of
measurement. Monolayers of papain treated cells are intact and cells are
viable as demonstrated by calcein uptake, metabolization and retention
(panel A). No increase of LDH in the supernatant was apparent at
enzyme concentrations of up to 25 μg/mL (panel B).
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viable as demonstrated by calcein uptake, metabolization
and retention. No detachment from the vessel surface was
observed and cells retained a typical flat “cobblestone”
morphology. These findings are confirmed by the lactate
dehydrogenase (LDH) release assay which would be indi-
cative for cell lysis (Figure 1B). No significant increase of
LDH in the supernatant could be observed at concentra-
tions of up to 25 μg/mL papain. These data demonstrate
that papain does not damage cells under our test condi-
tions, even under prolonged incubation times.
Receptor integrity
Plant derived proteases are known to interfere with the
expression of surface receptors of immunocompetent
cells [17] therefore we investigated the expression of
VEGF receptor 2 on HUVEC after 4 hour incubation
with medium containing 10 μg/mL papain. HUVEC
stained positive for VEGF receptor 2 (Figure 2) indicat-
ing that VEGF-receptor 2 is not shedded from the cell
surface under our test conditions.
Pathway activation
Next we investigated the effect of pre-incubation with
papain on the phosphorylation status of key regulatory
proteins AKT1, MEK, p38-MAPK, SAPK/JNK and
STAT3 (Figure 3). Four hours pre-incubation with pa-
pain lead to a significantly reduced phosphorylation of
MEK1 and p38-MAPK after activation with VEGF (2.13
vs 1.58 fold control resp. 1.32 to 1.14 fold control).
Phosphorylation of AKT1 (1.28 vs. 0.94 fold control)
and SAPK/JNK (1.77 vs 1.34 fold control) was reduced,
although significance levels varied between 0.05 and
0.15. Surprisingly, ERK1/2 was significantly up-regulated
(1.23 vs 1.50 fold control, p<0.05).
Cell proliferation
A switch from quiescence to proliferation is the first step
in angiogenic activation. Whereas the anti-inflammatory
action of plant proteases is well documented, much less
is known about their effect on cell growth. We therefore
investigated the effect of papain on the proliferation of
VEGF stimulated endothelial cells (Figure 4). HUVEC
were treated with 10 ng/mL VEGF with or without
addition of papain at the indicated concentrations. Pa-
pain exerts a significant inhibition of proliferation at
concentrations between 6.25 μg/mL and 100 μg/mL with
an IC50 at 7.5 μg/mL Papain. At 100 μg/mL, metabolic
activity as indicated by MTT metabolization was slightly
below the untreated control. This is indicative for
complete growth inhibition since endothelial cells in
media lacking growth factors are not completely
quiescent.
AB
Figure 2 Effect of papain on the expression of VEGF-receptor 2.
HUVEC were seeded into fibronectin coated 8-well chamber slides and
cultured in EGM. After 24 hours, medium was changed and 10 ng/mL
VEGF or a combination of 10 ng/mL VEGF and 10 μg/mL papain. After
1 hour, cells were fixed with 2% paraformaldehyde and stained with
primary mouse antibody against VEGFR2 and FITC labeled goat anti
mouse secondary antibody (Panel B). Cell nuclei were counter stained
using DAPI. Unspecific mouse IgG served as isotype control (Panel A).
Although there is slight unspecific binding of secondary antibody
visible on the isotype control, VEGFR2 was clearly present on cells after
treatment with 10 μg/mL papain.
Figure 3 Effect of pre-treatment of papain on the
phosphorylation status of key-regulatory proteins. HUVEC were
seeded into fibronectin coated 25 cm2 tissue culture flasks and
cultured in EGM. After 24 hours medium was changed to EBM
containing 10 μg/mL Papain and cells were incubated for further
four hours. Cells were washed with PBS to remove papain and
treated for 15 minutes with EBM containing 10 ng/mL VEGF.
Untreated cells served as control. Protein was isolated and
phosphorylation was measured using a multipathway ELISA kit. Data
are shown as mean ± standard error of measurement with the
numbers indicating p-values, black bars indicating VEGF treatment
alone and open bars indicating pre-treatment with papain.
Pretreatment with papain profoundly interferes with the ability of
cells to respond to angiogenic stimuli. Phosphorylation of MEK1 and
p38-MAPK were significantly downregulated, whereas ERK1/2 was
significantly upregulated. Phosphorylation of Akt1 and SAPK/JNK was
also downregulated but with p-values between 0.1 and 0.15.
Figure 4 Effect of papain on cell proliferation of HUVEC. HUVEC
were seeded into fibronectin coated 96-well microtiterplates and
cultured in EGM. After 24 hours medium was changed to EBM
containing 10 ng/mL VEGF or 10 ng/mL VEGF and papain at
concentrations as indicated. After 72 hours, cell growth was assayed
using an MTT-assay kit. Data are shown as optical density at 450 nm
with a reference wavelength of 620 nm, mean ± standard error of
measurement. Papain exerts a significant inhibition of proliferation at
concentrations between 6.25 μg/mL and 100 μg/mL.
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The next step in angiogenesis is migration of endothelial
cells under influence of an angiogenic stimulus, there-
fore we investigated the effect of papain on cell mi-
gration (Figure 5A and B). HUVEC were treated with
10 ng/mL VEGF with or without addition of papain at
the indicated concentrations. Papain showed a statistical
Figure 5 Effect of proteolytic enzymes on cell migration and tube formation in HUVEC. HUVEC were seeded into fibronectin coated
12-well microtiterplates and cultured in EGM. After 24 hours medium was changed to EBM. Cells were stained using calcein-AM, the monolayer
was scratched with a 200 μL pipette tip and photographed at 10 fold magnification using a Nikon Eclipse Ti as described above. After 14 hours
culture in EBM containing 10 ng/mL VEGF or 10 ng/mL VEGF and papain and photographed. covered area was measured using the TScratch
software package, results were calculated as percent open area. Data are shown as mean ± SEM. Panel A shows photomicrographs at the
beginning of the assay (column start) and after 14 hours incubation (column end) for cells treated with either 10 ng/mL VEGF or 10 ng/mL VEGF
and 10 μg/mL papain. Migration fronts are marked by white lines. Panel B shows the percentage open area. Papain inhibited cell migration
almost completely at a concentration of 10 μg/mL. Angiogenesis slides were coated with 10 μL Matrigel per well and incubated for 30 min at 37°
C. Endothelial cells were and seeded into the wells at a density of 5000 cells per well in EBM containing 10 ng/mL VEGF. After 4 hours
preincubation, papain was added at concentrations as indicated. After a further 20 hour incubation period, cells were labelled with 2 μM Calcein-
AM. Micrographs of fluorescent cells were taken at 4 fold magnification using a Nikon Eclipse Ti as described above. Tube formation was
quantified by the angiogenesis analyzer plugin for ImageJ. Panel C shows photomicrographs for the control, treatment with 10 ng/mL VEGF and
with 10 ng/mL VEGF in combination with 1 and 10 μg/mL papain. Panel D shows the measured network length as percentage untreated control.
Tube length decreased significantly to control levels after treatment with 1 μg/mL papain. At concentrations of 10 μg/mL tube formation was
almost completely abrogated.
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of 10 μg/mL. At 1 μg/mL a slight inhibitory effect could
be observed, however, it was not significant.
Tube formation
To cover the final step of angiogenesis we investigated
the effect of Papain on tube formation (Figure 5C and D).HUVEC were treated with 10 ng/mL VEGF with or
without addition of papain at the indicated concentra-
tions. VEGF significantly stimulated the formation of
tubes. Network formation was inhibited significantly
at a concentration of 1 μg/mL or papain. A concentra-
tion of 10 μg/mL abrogated tube formation almost
completely.
Figure 6 Effect of other plant derived proteolytic enzymes on
cell growth and tube formation of HUVEC. HUVEC were seeded
into fibronectin coated 96-well microtiterplates and cultured in EGM.
After 24 hours medium was changed to EBM containing 10 ng/mL
VEGF or 10 ng/mL VEGF and bromelain respectively ficin at
concentrations as indicated. After 24 hours, cell growth was assayed
as described above. Data are shown as mean ± standard error of
measurement. Treatment with bromelain as well as ficin resulted in
a significant inhibition of proliferation at concentrations between
10 μg/mL and 25 μg/mL (Panel A). Panel B shows the effect of
bromelain and ficin on tube formation, assayed as described above.
Briefly, after 4 hours preincubation bromelain respectively ficin was
added at concentrations as indicated. Data were measured as
network length and shown as mean percent control ± standard
error of measurement. Treatment with 1μg/mL bromelain inhibited
tube formation significantly to control levels. At concentrations of
10 μg/mL bromelain or ficin tube formation was almost
completely abrogated.
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Finally we investigated the capability of other plant de-
rived cysteine proteases to inhibit endothelial cell growth
(Figure 6A) and tube formation (Figure 6B). Bromelain
as well as ficin inhibited growth of endothelial cells. We
could determine the IC50 with 21.30 μg/mL for brome-
lain and 24.22 mg/mL for ficin. Both enzymes signifi-
cantly inhibited tube formation at a concentration of
10 μg/mL. Bromelain exerted significant inhibition of
tube formation already at a concentration of 1 μg/mL.
Discussion
Plant derived cysteine proteases, especially bromelain
have been used for decades in complimentary medicine
as a remedy for inflammatory diseases. However, the
mode of action by which plant cysteine proteases act is
not well understood. Several mechanisms have been pro-
posed: Cleavage of proteins from the cell surface [18],
Interference with key components of pathways [21,22]
and direct cytotoxicity via induction of apoptosis [23].
To address these questions we investigated direct cyto-
toxicity of papain towards endothelial cells. Prolonged
incubation of endothelial cells with concentrations of up
to 25 μg/mL papain did not result in increased release of
lactate dehydrogenase which would be indicative for cell
lysis. Additionally MTT assays showed that papain at
concentrations of up to 100 μg/mL did suppress cell
growth only to slightly below untreated control. These
results are in line with other studies were protease con-
centrations of up to 400 μg/mL have been used [23].
Next we investigated the possibility of proteolytic re-
moval of the main receptor for VEGF mediated angio-
genesis, VEGFR2. Indeed, immunofluorescent staining
showed that VEGFR2 remains on the cell surface even
after prolonged incubation with papain.
We then investigated the phosphorylation status of
AKT1, ERK1/2, MEK1/2, p38-MAPK and SAPK/JNK
after pre-treatment with papain and found a modulation
of phosphorylation levels of AKT1, MEK1/2, p38-MAPK
and SAPK/JNK (down-regulated) and ERK1/2 (up-
regulated). The PKB/AKT pathway is one of the main sig-
naling pathways activated by VEGFR2 [8]. Down-
regulation of AKT phosphorylation by cysteine proteases
has been observed in other cells models in context with
blocking NF-κB activation and subsequent induction of
apoptosis [23]. However, in context of the VEGF receptor
2 signaling cascade, AKT phosphorylates BAD and
caspase9 thus inhibiting their apoptotic activity. Addition-
ally AKT phosphorylates the FOXO family of proteins
which leads to their inactivation and a decrease in tran-
scription of proteins promoting apoptosis [29]. In this
context AKT acts as an inhibitor of apoptosis and is cru-
cially required for VEGF mediated angiogenic activation
[30-32]. Targeting AKT inhibits angiogenesis in vivo [33].VEGF additionally signals via Ras → c-RAF→ MEK →
ERK [8]. An effect of cysteine proteases on this pathway
has first been reported by Mynott et al. in a T-cell model
[34]. In this model, treatment with bromelain down-
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IFN-γ, and IL-4 mRNA accumulation. Since trypsin had
no effect, Mynott could exclude unspecific proteolysis.
Our data suggest that down-regulation of this signaling
pathway includes down-regulation of MEK1/2 activity.
MEK1/2 are protein kinases that mediate the phosphoryl-
ation of ERK1 or ERK2. This activates ERK1/2, which are
protein-serine/threonine kinases with a broad spectrum of
cytosolic and nuclear substrates. Interestingly we observed
an up-regulation of ERK1/2 phosphorylation. This differs
from the situation reported in other cell models and
in vivo where a marked inhibition of ERK1/2 has been ob-
served [21,34]. The reason for this observation may be the
down-regulation of p38-MAPK which serves negative
regulator for ERK1/2 [35].
Both p38-MAPK and JNK are mainly involved in cel-
lular response to many types of stresses, but they also
control proliferation, differentiation, survival and migra-
tion of specific cell types. Aside cellular stress JNK as
well as p38 MAPK pathways can be activated by growth
factors [36]. The role of SAPK/JNK in angiogenesis is
not fully understood yet. Boyd et al. found that JNK in-
hibition lead to inhibition of tube formation [37] leading
to the conclusion of JNK being a positive regulator of
angiogenesis. This is underlined by the fact that inhib-
ition of JNK significantly decreased endothelial prolifera-
tion and migration [38]. We observed a down-regulation
of SAPK/JNK which cold in part explain the reduced mi-
gration and tube formation we observed.
Activation of p38-MAPK induces endothelial cell migra-
tion [39] and serves as a negative regulator for ERK1/2 and
AKT in VEGF mediated angiogenesis [35]. On the other
hand, in endothelial cells exposed to chronic inflammatory
activation p38-MAPK acquires a pro-angiogenic role [40].
We observed a down-regulation of p38-MAPK which is in
line with published observations in other models [21].
Finally we investigated whether these data translate
into altered endothelial cell function (cell growth, cell
migration and capability to form tubes). Papain inhibited
cell growth in a concentration response dependent man-
ner with an IC50 of 7 μg/mL. Cell migration was almost
completely abrogated at a concentration of 10 μg/mL
and tube formation was significantly inhibited at a con-
centration of 1 mg/mL. At a concentration of 10 μg/mL,
tube formation was almost completely abrogated. Inhib-
ition of cell growth and tube formation could also be
seen in bromelain and ficin treated endothelial cells,
pointing towards antiangiogenic properties of plant de-
rived cysteine proteases in general.
Conclusion
Papain displayed a strong anti-angiogenic effect in VEGF
activated HUVEC which could also be seen with brome-
lain and ficin. This effect is likely caused by interferencewith key signaling pathways AKT, MEK, ERK1/2, p38-
MAPK and SAPK/JNK signaling. These findings indicate
that plant proteolytic enzymes effectively interfere with
angiogenesis and that these proteases may have potential
as preventive and therapeutic agents in diseases involv-
ing pathological angiogenesis.
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